Quantitative chimerism: an independent acute leukemia prognosis indicator following allogeneic hematopoietic SCT
Authors:
- 4 August 2014
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 49 (10) , 1269-1277
Abstract
This study evaluates the prognostic significance of quantitative chimerism to monitor minimal residual disease and predict relapse in acute leukemia (AL) patients following allogeneic hematopoietic SCT (HSCT). The quantitative chimerism levels of 129 AL patients were measured using RQ-PCR based on 29 sequence polymorphisms. Receiver-operating characteristic curve indicated that the optimal cutoff point to predict an inevitable relapse was 1.0%, which results in 100.0% sensitivity and 79.6% specificity.The relapse rate of patients with chimerism >1.0% at 2 years was 55.0%, whereas that for patients with chimerism 1.00% indicated a higher probability of relapse. Cox multivariate analysis indicated that quantitative chimerism >1.00% was associated with lower disease-free survival (hazard ratio (HR)=10.825; 95% confidence interval (CI) =4.704-24.912, P=0.000) and lower OS (HR=8.681; 95% CI=3.728-20.212, P=0.000). Patients (24/47 with quantitative chimerism >1.00%) who received preemptive modified DLI immunotherapy had significantly lower relapse rate (37.5%) than those (n=9) who did not (100%; P=0.001). Thus, quantitative chimerism is an independent prognostic factor that predicts clinical outcomes after HSCT and provides a guide for suitable interventions.Keywords
This publication has 59 references indexed in Scilit:
- Risk stratification–directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantationBlood, 2012
- Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantationBlood, 2011
- Wilms’ tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCTBone Marrow Transplantation, 2011
- Minimal Residual Disease following Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2011
- Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemiaExperimental Hematology, 2010
- Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisitedCancer Treatment Reviews, 2010
- Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effectiveBone Marrow Transplantation, 2004
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphismsLeukemia, 2003
- Additional immunotherapy on the basis of increasing mixed hematopoietic chimerism after allogeneic BMT in children with acute leukemia: is there an option to prevent relapse?Bone Marrow Transplantation, 1997